Bioplus (CEO Jeong Hyeon-gyu) announced that it has obtained ‘Good Manufacturing Practice (GMP)’ certification for its local factory located in the Hainan Medical Tourism Special Zone in China.
Previously, Bioplus had undergone an on-site inspection of its Hainan factory for medical device grade 2 GMP from the Chinese health authorities, and completed final certification in March. With this Hainan factory GMP certification, Bioplus plans to supply products produced at its local factory throughout China.
In particular, the company plans to attack the Chinese market by accelerating the mass production of its own cosmetics brand Bonyx and Skin Booster products, which have acquired Class 2 medical device manufacturing and sales approval.
Additionally, the plant is in the process of obtaining GMP approval for a Class 3 medical device and a cosmetics production facility, which will likely enable it to secure additional production lines.
“We are encouraged that we have secured a local GMP-certified production facility at a time when expectations are growing for the lifting of THAAD restrictions and the opening of the Chinese market,” said Hwang Young-ki, head of Bioplus’ Global Business Division. “As we will be able to produce Bioplus’ products locally and supply them throughout China, we expect the plant to serve as a forward base for our entry into the Chinese market.”
In addition, Bioplus announced that it is in the process of obtaining Class 3 medical device product approval from the China National Medical Products Administration (NMPA) to expand export items to China, and that it plans to focus its business capabilities on expanding its market share in China in the future.
- See more related articles
You must be logged in to post a comment.